Who Paid My Doc
NovoSeven
Biological Hemophilia
NDC 0169-7010-01
General payments
$583,298
Research payments
$926,724
Through program year 2025, $583,298 in general payments and $926,724 in research payments were reported against NovoSeven (Hemophilia).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $95,699 | 96 |
| 2025 | Research | $21,745 | 5 |
| 2024 | General | $126,017 | 173 |
| 2023 | General | $141,301 | 273 |
| 2022 | General | $134,597 | 209 |
| 2021 | General | $85,684 | 191 |
| 2021 | Research | $904,979 | 3 |
Breakdown
The top 5 of 64 recipients; each share is of general payments naming this product in 2025.
The top 5 of 28 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 18 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
942 general · 8 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.